Artera received a FDA Breakthrough Designation for AI prostate test (an AI-enabled tool designed to assist clinicians in making risk-based decisions for patients with localized prostate cancer). Artera’s Breakthrough designation for ArteraAI Prostate was announced July 9th is noteworthy because Artera announced today a de novo classification authorization dated July 31st for the ArteraAI Prostate. I’ll be interested to see this de novo public release of classification order and/or decision summary whenever available to get more information on this product, unfortunately that could be a long time as de novo public document releases have been extremely slow to happen since January 2025. I can’t say I’ve ever seen a FDA Breakthrough Device Designation announcement by a company followed by a FDA marketing authorization just 3 weeks later, but it is an interesting strategy if Artera was far along in their de novo process with a near term likely positive outcome to go after BDD as well. I could see this BDD pursuit being valuable for a near imminent de novo authorization in (A) the reimbursement benefits a BDD grant confers and / or (B) to accelerate FDA discussions for future indications / clinical studies to support ArteraAI Prostate follow on 510(k) submissions that may evolve after de novo classification.
August 11, 2025
